Administering Non-invasive Ventilation (NIV)
Published: 20 April 2023
Published: 20 April 2023
Non-invasive ventilation (NIV) is the delivery of respiratory support to a patient using an external interface (mask or helmet).
Unlike invasive mechanical ventilation (IMV), which involves the insertion of an artificial airway (endotracheal tube or tracheostomy), NIV does not interfere with the patient’s upper airways and preserves their ability to speak, cough and swallow (Soo Hoo 2020; Gregoretti 2015).
NIV may be administered to a patient who is having difficulty ventilating and oxygenating due to acute respiratory distress, chronic respiratory conditions, surgical complications, asthma, comfort care or another respiratory failure. It may also be used to wean a patient off mechanical ventilation (ACI 2023).
NIV should be considered in the early stages of respiratory decline to minimise intensive care admission.
NIV may alleviate some of the physiological effects of respiratory failure, including reducing the work of breathing and reversing hypoxia (Nickson 2019).
Early and successful implementation of NIV has been shown to decrease intubation rates and reduce the duration of intensive care unit and hospital stays. Furthermore, NIV has also been attributed to reduced rates of in-hospital morbidity and mortality (Comellini et al. 2019).
However, early detection of patient deterioration is crucial to ensure that oxygenation and ventilation are optimised.
NIV may also avert the risk of developing infections and complications associated with IMV such as pneumonia (Gregoretti 2015).
Successful implementation of NIV has been attributed to choosing an appropriate interface for the patient and providing adequate education to the patient to promote comfort and adherance with the device. The four types of interface used include:
(ACI 2023)
Each interface has both advantages and disadvantages. Generally, oronasal masks are most preferable for patients with acute respiratory failure and are relatively successful, but may be uncomfortable. Conversely, nasal masks are more comfortable but more likely to lead to NIV failure, often due to mouth leaks (ACI 2023).
It is important to be aware of factors that may contribute to interface intolerance by patients, including claustrophobia, poor fit, discomfort and oronasal dryness. Pressure injuries are common when using oro-nasal and nasal masks (ACI 2023).
Before delivering NIV, the patient must be assessed for:
(ACI 2023)
If the patient fails to meet one of these criteria, they are ineligible for NIV and alternate care should be sought.
The process of administering NIV is as follows:
(ACI 2023; Rochwerg et al. 2017)
Generally, NIV is tolerated well by most patients. However, adverse effects are possible (Carron et al. 2013).
Patients who have a decreased level of consciousness secondary to raised carbon dioxide levels, or are confused or hypoxic, are at increased risk of developing complications and require constant observation until their condition improves (ACI 2023).
NIV may cause haemodynamic instability in patients with acute respiratory failure (Carron et al. 2013).
If the patient does not clinically improve after starting NIV, therapy may need to be escalated. If the patient continues to deteriorate despite therapy, call for assistance. The patient may need to be intubated and invasively ventilated (ACI 2023).
In the event of an escalation, the patient may be transferred to a critical care setting where higher staffing ratios and more complex interventions are available (ACI 2023).
Overall, nurse knowledge, understanding and communication, as well as patient comfort and compliance, are key in determining the success of NIV.
Note: This article is intended as a refresher and should not replace best-practice care. Always refer to your facility’s policy on non-invasive ventilation.
Question 1 of 3
Which one of the following interfaces is generally preferable for patients with acute respiratory failure?